Linda Powers came in at a time the company needed to be saved. She developed a Government/NASA like relationship between researchers and manufacturers in order to protect the company further -- absorb cost, pay with shares, debts that were overdue -- in other words she very cleverly accomplished/achieved support for what needed to be one of the longest trials time to survive, all the while she expanded NWBO's influence by helping to develop/utilize two brand new international early access programs, in order to ramp a brand new disruptive autologous therapy only capable of wide distribution through a potential/eventual hard and fast commercial launch.
Undoubtedly, Neil Woodford's people will find creative financing that NWBO used to survive from 2007 into 2015, but if they are not cutthroat, their goal is not a hostile takeover, and instead clearing out the cobwebs and taking this company to the next level.
In creating the patient investor fund, Neil Woodford was looking for companies that were really good at science, but perhaps in need of the type of consultant resources and direction his team and subcontractors can provide.
I see his philosophy winning the day, the cobwebs are in need of dusting and a renewed company, not arising from the ashes, but forged from fire.
There are many other ways this could go, but for now, I'm assuming LP and NW are moving this company from biotech startup to commercial juggernaut.
Meanwhile, I expect the science to prove our oncological therapeutic expectations correct.
News 
Market Data 
Discover 
AI
